Jenthera viral gene editing program

Jenthera Therapeutics' undisclosed viral program is an early-stage in vivo gene editing therapy currently in the lead compound phase of preclinical development. The program leverages Jenthera's proprietary CRISPR/HDR platform, which focuses on the systemic delivery of CRISPR ribonucleoproteins (RNPs) to achieve precise genetic modifications. While the specific viral disease and molecular target have not been disclosed, the approach aims to utilize targeted gene editing to address viral infections directly within the patient's body. The platform is designed to overcome traditional delivery challenges by using a non-viral, RNP-based system for therapeutic genome engineering.

Other names

Unnamed Program (Viral Target)Jenthera Therapeutics-undisclosed viral target-in vivo gene editing-undisclosed viral disease